In 250 patients with diabetes and cirrhosis of different severity, continuing use of metformin significantly reduced all-cause mortality, and longer survival extended to Child B/C patients, after adjusting for confounders (hazard ratio [HR], 0.43; 95% CI, 0.24-0.78).40 Metformin was also reported to reduce the incidence of hepatic encephalopathy in a cohort of 82 patients with cirrhosis and T2D, possibly via inhibition of glutaminase activity.41 This evidence concerns the gene GLS and Cirrhosis.